Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseases

Abstract Neovascular age-related macular degeneration (AMD) is a progressive eye disease and is a leading cause of vision loss in the Western world. Vascular endothelial growth factor inhibitors have become a mainstay of treatment for this disease. Currently, treatment options include three originat...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of law and the biosciences 2022-01, Vol.9 (1), p.lsac001-lsac001
Hauptverfasser:	Van de Wiele, Victor L, Hammer, Maximilian, Parikh, Ravi, Feldman, William B, Sarpatwari, Ameet, Kesselheim, Aaron S
Format:	Artikel
Sprache:	eng
Schlagworte:	Antitrust law Biological products Brand name products Care and treatment Drug approval Evaluation Laws, regulations and rules Original Prescription pricing Prices and rates Retinal diseases Treatment outcome Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!